Locren Capsule SR is a sustained-release formulation combining Aceclofenac 200mg and Rabeprazole 20mg, designed to provide effective management of inflammatory conditions accompanied by gastric acid-related symptoms. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by selectively inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis responsible for pain and inflammation. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing gastroprotection against NSAID-induced gastric mucosal damage. This combination is particularly beneficial in patients requiring long-term NSAID therapy who are at risk of developing gastrointestinal complications such as gastritis or peptic ulcers. Locren Capsule SR is indicated for conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal disorders requiring anti-inflammatory treatment while minimizing gastrointestinal side effects. The sustained-release mechanism ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control. It is recommended to administer Locren Capsule SR as prescribed by a healthcare professional, with caution advised in patients with known hypersensitivity to NSAIDs or proton pump inhibitors, and in those with pre-existing hepatic, renal, or cardiac conditions. Regular monitoring is advised during prolonged therapy.